Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Medical University of Vienna |
---|---|
Information provided by: | Medical University of Vienna |
ClinicalTrials.gov Identifier: | NCT00813514 |
Age related macular degeneration (AMD) is a multifactorial disease with a strong genetic component. Most importantly a genetic polymorphism in the gene encoding for the complement factor H (CFH) has been recently identified which is highly associated with an increased risk of developing AMD. This Tyr402His polymorphism located on chromosome 1q31 has been implicated to play a role in the development of the disease.
For this purpose a total of 200 patients with wet AMD will be included in the study. As described in detail below, the current study aims to identify potentially non-responders to anti-VEGF therapy based on genetic analysis of VEGF polymorphism and complement factor H polymorphism.
Condition | Intervention |
---|---|
Choroidal Neovascularization Age-Related Macular Degeneration |
Genetic: VEGF genotyping |
Study Type: | Interventional |
Study Design: | Diagnostic, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | Does VEGF or Complement Factor H Gene Polymorphism Play a Role in the Treatment Success With VEGF Inhibitors in Patients With CNV? |
Estimated Enrollment: | 200 |
Study Start Date: | January 2009 |
Estimated Study Completion Date: | January 2010 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: No Intervention
Open longitudinal study with observer masked analysis
|
Genetic: VEGF genotyping
blood sample for gene analysis
|
Ages Eligible for Study: | 50 Years to 90 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Gerhard Garhöfer, MD | +431404002981 |
Austria | |
Department of Clinical Pharmacology, Medical University of Vienna | |
Vienna, Austria |
Principal Investigator: | Leopold Schmetterer, Prof. Dr. | Department of Clinical Pharmacology |
Responsible Party: | Department of Clinical Pharmacology, Medical University Vienna, Austria ( Dr. Fuchsjäger- Mayrl ) |
Study ID Numbers: | OPHT-270907 |
Study First Received: | December 22, 2008 |
Last Updated: | December 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00813514 |
Health Authority: | Austria: Agency for Health and Food Safety |
AMD VEGF genotyping complement H gene polymorphism Vascular Endothelial Growth Factor A |
Metaplasia Eye Diseases Choroid Diseases Retinal Degeneration Macular Degeneration Neovascularization, Pathologic |
Endothelial Growth Factors Complement Factor H Retinal Diseases Retinal degeneration Choroidal Neovascularization |
Uveal Diseases Pathologic Processes Immunologic Factors Growth Substances |
Physiological Effects of Drugs Immunosuppressive Agents Complement Inactivating Agents Pharmacologic Actions |